(E/Z)-4-HTA monohydrate

• 产品号: H5039
• 分子式: C24H24O5
• 分子量: 392.44436
• 纯 度: ≥90% (HPLC)

产品别名

• 标题: (E/Z)-4-HTA monohydrate
• IUPAC标准名: 2-{4-[1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl]phenoxy}acetic acid hydrate
• IUPAC传统名: 4-[1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl]phenoxyacetic acid hydrate
• 别名: 4-Hydroxytamoxifen acid; (E,Z)-2-[4-[1-(p-Hydroxyphenyl)-2-phenyl]-1-butenyl]phenoxyacetic acid

产品登记号

• PubChem SID: 24724502

产品性质

• Empirical Formula (Hill Notation): C24H22O4 · H2O
• 纯度: ≥90% (HPLC)
• 外观: solid
• 溶解度: DMSO: >6 mg/mL
• GHS警示词: Warning
• GHS危险声明: H410
• 欧盟危险性物质标志: 环境危害性(Nature polluting) (N)
• 个人保护装置: Eyeshields, Gloves
• GHS警示性声明: P273-P501
• RID/ADR: UN 3077 9/PG 3
• 危险公开号: 50/53
• 安全公开号: 36/37-60-61
• 保存温度: 2-8°C
• 联合国危险货物等级: 9
• 联合国危险货物编号: 3077
• 联合国危险货物包装类别(PG): 3
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Biochem/physiol Actions
4-hydroxytamoxifen acid is a preferred tamoxifen analog, a nonsteroidal estrogenic compound for use in estrogen replacement therapy, and specifically menopause therapy. The estrogen replacements are administered to patients as the free acid or a pharmaceutically acceptable salt in combination with pharmaceutical carriers to alleviate conditions associated with a low level of estrogen, including osteoporosis, premenstrual syndrome, vasomotor symptoms associated with menopause, atrophic vaginitis, Kraurosis vulvae, female hypogonadism, primary ovarian failure, excessive hair growth and prostatic cancer.

详细说明 (简体中文)

Biochem/physiol Actions
4-hydroxytamoxifen acid is a preferred tamoxifen analog, a nonsteroidal estrogenic compound for use in estrogen replacement therapy, and specifically menopause therapy. The estrogen replacements are administered to patients as the free acid or a pharmaceutically acceptable salt in combination with pharmaceutical carriers to alleviate conditions associated with a low level of estrogen, including osteoporosis, premenstrual syndrome, vasomotor symptoms associated with menopause, atrophic vaginitis, Kraurosis vulvae, female hypogonadism, primary ovarian failure, excessive hair growth and prostatic cancer.